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Campylobacter jejuni has been identified as the predominant cause of antecedent infection in Guillain-Barre´
syndrome (GBS) and Miller Fisher syndrome (MFS). The risk of developing GBS or MFS may be higher after
infection with specific C. jejuni types. To investigate the putative clonality, 18 GBS- or MFS-related C. jejuni
strains from The Netherlands and Belgium and 17 control strains were analyzed by serotyping (Penner and
Lior), restriction fragment length polymorphism analysis of PCR products of the flaA gene, amplified fragment
length polymorphism analysis, pulsed-field gel electrophoresis, and randomly amplified polymorphic DNA
analysis. Serotyping revealed 10 different O serotypes and 7 different Lior serotypes, thereby indicating a lack
of serotype clustering. Two new O serotypes, O:35 and O:13/65, not previously associated with GBS or MFS
were found. Serotype O:19 was encountered in 2 of 18 strains, and none was of serotype O:41. The results of
all genotypic methods also demonstrated substantial heterogeneity. No clustering of GBS- or MFS-related
strains occurred and no molecular marker capable of separating pathogenic GBS or MFS from non-GBS- or
non-MFS-related enteritis strains could be identified in this study. Sialic-acid-containing lipopolysaccharides
(LPS) are thought to be involved in the triggering of GBS or MFS through molecular mimicry with gangliosides
in human peripheral nerves. Therefore, further characterization of GBS- or MFS-related C. jejuni should target
the genes involved in the synthesis of LPS and the incorporation of sialic acid.
The Guillain-Barre´ syndrome (GBS) is the most frequent
form of acute inflammatory polyneuropathy. The Miller Fisher
syndrome (MFS) is considered a rare variant of GBS. GBS and
MFS patients demonstrate a heterogeneous clinical presenta-
tion and outcome (28). Campylobacter jejuni infections in GBS
are associated with the presence of antibodies to GM1 and
other peripheral nerve gangliosides (10, 11). These antibodies
presumably are induced by the infectious agent since C. jejuni
lipopolysaccharide (LPS) from GBS and MFS patients shows
molecular mimicry with several gangliosides (17).
C. jejuni is the most frequent cause of bacterial diarrhea.
Approximately 1 in every 1,000 C. jejuni infections will be
followed by GBS (15). Several authors have hypothesized that
GBS-related C. jejuni strains share specific features by which
they induce antibodies cross-reactive with peripheral nerve
tissue. GBS-related C. jejuni strains have been reported to be
associated with the specific Penner serotypes O:19 and O:41,
and these appeared to be clonally related (6, 12, 24). The risk
of developing GBS may be higher after infection with serotype
O:19 (15).
Unfortunately, the time between the preceding intestinal
infection and the onset of GBS often exceeds the duration of
excretion of viable C. jejuni cells in stools. Thus, the number of
GBS-related C. jejuni isolates available for further study is
limited.
The aim of the study was to investigate the genetic variation
among these strains by using serotyping and various genotyp-
ing methods, including a flagellin typing method that deter-
mines polymorphisms in the flaA gene (3), amplified fragment
length polymorphism (AFLP) analysis (which has recently
been adapted for genotyping of Campylobacter spp. [4]),
pulsed-field gel electrophoresis (PFGE), and randomly ampli-
fied polymorphic DNA (RAPD) analysis (3–5, 7).
MATERIALS AND METHODS
Bacterial strains. In order to maximize the number of isolates, we prospec-
tively cultured stool specimens of patients presenting with GBS or MFS, starting
in 1994 and using a variety of sensitive and selective culture techniques, including
broth enrichment and mechanical filtration. We collected 18 GBS- or MFS-
related C. jejuni strains from patients in The Netherlands and Belgium. The 18
clinical C. jejuni strains analyzed in this study were isolated in the acute phase of
the disease from the stools of 17 Dutch patients and 1 Belgian patient between
1991 and 1998. All patients had a history of diarrhea prior to the onset of GBS
or MFS and/or anti-Campylobacter antibodies, which is suggestive of a recent
infection (1). Four C. jejuni isolates were isolated from patients with MFS, and
12 were from patients with GBS. Two isolates came from the diarrheal stools of
two family members of a GBS patient who remained culture negative throughout
but showed a serological response highly suggestive of a recent Campylobacter
infection (1). In addition, nine C. jejuni isolates from unrelated enteritis patients
without neurological symptoms and eight reference C. jejuni O serotypes were
included. All GBS patients fulfilled the diagnostic criteria (2). All MFS patients
suffered from ophthalmoplegia, ataxia, and areflexia (14).
Serotyping. All strains were serotyped with the heat-stable (HS or O) and
heat-labile (HL) serotyping schemes of Penner and Lior, respectively. The se-
rotyping was performed at the National Laboratory for Enteric Pathogens, Ca-
nadian Science Centre for Human and Animal Health, Winnipeg, Canada, as
described previously (13, 22).
Bacterial DNA isolation. Chromosomal DNA was isolated with the Wizard
Genomic DNA purification kit according to the manufacturer’s instructions
(Promega, Madison, Wis.).
PFGE. PFGE was performed as previously described (26). In short, samples of
genomic DNA extracted from overnight cultures of the strains were digested with
SmaI (Boehringer GmbH, Mannheim, Germany). Electrophoresis was per-
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formed in 1% SeaKem agarose in 0.53 Tris-borate-EDTA buffer by using a
Bio-Rad CHEF mapper programmed in the auto-algorithm mode (run time,
19 h; switch time, 6.75 to 25 s). Gels were stained with ethidium bromide for 15
min, destained in distilled water for 1 h, and photographed under UV radiation.
The gels were inspected visually by two different investigators. The patterns were
interpreted according to the criteria described by Tenover et al. (25). Isolates
that differed by one to three bands, consistent with one single differentiating
genetic event, were assigned the same capital letter, but with a numbered sub-
type. Four or more band differences between two strains were defined as distinct
genotypes and were designated with different capital letters.
RAPD. RAPD was done in volumes of 50 ml containing 200 mM concentrations
of each deoxyribonucleoside triphosphate, 50 ng of template DNA, 2.5 U of Taq
DNA polymerase (Promega, Southhampton, United Kingdom), 1.5 mM MgCl2,
and 5 ml of reaction buffer (Promega). The primers used were the enterobacterial
repetitive intergenic consensus sequences ERIC-1 (59-ATGTAAGCTCCTGGG
GATTCAC-39) and ERIC-2 (59-AAGTAAGTGACTGGGGTGAGCG-39)
(18). Amplification was performed in a DNA thermal cycler (Perkin-Elmer 9600;
Perkin-Elmer, Norwalk, Conn.). The PCR program consisted of 4 min at 94°C,
followed by 40 cycles of 45 s at 94°C, 45 s at 25°C, and 1 min at 74°C. The PCR
products were analyzed by electrophoresis in 1% agarose gels. After staining with
ethidium bromide and destaining, photographs were made using UV transillu-
mination. Banding patterns were analyzed visually by two independent examin-
ers, and the profiles were designated by a different capital letter whenever a
single band difference was observed.
AFLP. AFLP has recently been adapted for genotyping of Campylobacter spp.,
and it generated fingerprints with 50 to 80 bands with sizes ranging from 50 to
500 bp.
The AFLP reactions were performed as described previously (4). The restric-
tion enzymes used were HindIII and HhaI. For DNA amplification, the HhaI
primer (59-GATGAGTCCTGATCGCA-39) and the fluorescently labelled
HindIII primer (59-GACTGCGTACCAGCTTA-39) were used. For selective
PCR amplification, both primers contained a single additional A nucleotide at
their 39 ends. AFLP fingerprints were analyzed on a 373A ABI DNA sequencer,
followed by numerical analysis of patterns. Strains with similarity levels of .90%
were defined as genetically related and assigned the same capital letter (4).
Strains that belonged to the same cluster, with .80% similarity, were defined as
genetic subtypes and assigned the same capital letter, but with a numbered
subtype. Distinct AFLP fingerprints that showed ,80% similarity were desig-
nated with different capital letters.
flaA PCR-RFLP. For DNA amplification, the flaA primer (59-CGTATTAAC
ACAAATGTTGCAGC-39) and flaR primer (59-GATTTGTTATAGCAGTTT
CTGCTATATCC-39) as described by Ayling et al. (3) were used. Reaction
mixtures consisted of 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.01% (wt/vol)
gelatin, 2 mM MgCl2, 0.2 mM deoxynucleoside triphosphates, 50 pmol of each
primer, 50 pg of genomic DNA, and 2.5 U of AmpliTaq DNA polymerase
(Perkin-Elmer, Gouda, The Netherlands), with a total reaction volume of 50 ml.
Reaction conditions were 60 s at 94°C, followed by 45 cycles of 45 s at 94°C, 45 s
at 55°C, and 2 min at 72°C, and a 5-min extension at 72°C. After verification of
the PCR, 12.5 ml of the amplicon was digested for 2 h at 37°C using 10 U of DdeI
(Boehringer) in a total volume of 15 ml. Restriction fragments were separated on
a 2% (wt/vol) NuSieve (FMC, Rockland, Maine) and 0.5% (wt/vol) MP (Boehr-
inger Mannheim, Germany) ethidium bromide-stained agarose gel in 13 Tris-
acetate-EDTA. Gels were electrophoresed for 4 h at 80 V, and images of the gels
were digitized and saved as TIFF files.
Distinct flaA fingerprints showing a single band difference were designated
with different capital letters.
Data processing. Levels of similarities between banding patterns were deter-
mined with the GelCompar v4.1 software (Applied Maths, Kortrijk, Belgium).
For analysis of AFLP fingerprints, the Pearson product-moment correlation
coefficient was used. The flaA, PFGE, and RAPD banding patterns were ana-
lyzed with the Dice band-based coefficient. Cluster analysis was performed with
the unweighted pair group method with averages (29).
RESULTS
Serotyping. Serotyping of 18 GBS- or MFS-related strains
revealed 10 different O serotypes and 7 different HL serotypes
(Table 1). C. jejuni O:19, Lior 77 was encountered in 2 of 18
(11%) patients. C. jejuni O:2 was found in one GBS patient, in
two family members of another GBS patient, and in one MFS
patient. C. jejuni O:4/64 was encountered in one GBS patient
and one MFS patient; the related C. jejuni O:4/13/64 strain was
found in one GBS patient. C. jejuni O:13/65 and O:35 were two
new serotypes not earlier described in association with GBS or
MFS (Table 1). Four patients with MFS had C. jejuni of dif-
ferent O serotypes (Table 1). All other strains had unique O
serotypes.
flaA PCR-RFLP. flaA PCR-RFLP analysis of 18 GBS- or
MFS-associated C. jejuni strains identified 12 distinct patterns
(Table 1; Fig. 1). Analysis of GB13 (O:2) and GB14 (O:2),
both strains isolated from family members of a GBS patient,
produced flaA patterns indistinguishable from those of GB17
(O:4/13/64) and MF 6 (O:4/64). The two O:19 strains (GB3
and GB18) showed identical flaA patterns that were also
shared with strains GB2 (O:UT) and GB16 (O:13/65), but not
with the O:19 reference strain. Other GBS strains had flaA
patterns that were highly related to flaA patterns of enteritis-
related strains and reference serotype strains (Table 1; Fig. 1).
The heterogeneity of flaA patterns of the GBS and MFS strains
was comparable to that of the enteritis and Penner reference
strains. With cluster analysis, no specific flagellin type was
present among the GBS- or MFS-related Campylobacter
strains tested (Fig. 1).
AFLP. AFLP detected 12 distinct fingerprints within the 18
GBS or MFS C. jejuni strains. Two small clusters of strains
were found (Table 1). The O:19 GBS strains (GB3 and GB18)
and O:19 serostrain showed highly related AFLP fingerprints.
A high level of homology was also observed when comparing
AFLP fingerprints of GB13, GB14, GB16, GB19, and the O:2
serostrain. Although strain GB11 showed some band differ-
ences compared to the patterns of GB13 and GB14, a genetic
relationship between these strains was evident. Two GBS
strains, GB1 and GB15, and strain MF20 shared AFLP finger-
prints with some of the enteritis strains (Table 1). Cluster
analysis showed no separate clustering of GBS- and MFS-
related strains. Within each cluster of AFLP fingerprints,
strains from GBS and MFS patients as well as reference sero-
type strains and strains from enteritis patients were present.
RAPD and PFGE. The PFGE analysis of 18 GBS- or MFS-
related C. jejuni strains revealed the presence of 15 distinct
types (Table 1). The two C. jejuni O:2, Lior 4 strains (GB13
and GB14), isolated from family members of a GBS patient,
were indistinguishable from each other and were related to
GB11. However, these strains were unrelated to MF20, a strain
with the same O and HL serotypes. C. jejuni GB5, isolated
from a GBS patient, appeared subclonally related to C. jejuni
MF6, a strain obtained from a patient with MFS. With com-
puter-aided analysis, no clustering of GBS- or MFS-related
strains was found. With the RAPD analysis of the 18 GBS or
MFS strains, 15 (ERIC-1) and 13 (ERIC-2) distinct types were
obtained (Table 1). No clustering of GBS or MFS strains was
found by computer analysis.
DISCUSSION
This study illustrates the substantial heterogeneity of C. je-
juni strains associated with GBS or MFS in a restricted geo-
graphical area of the world. Of the GBS- or MFS-related
strains in our study, 2 of 18 (11%) were of serotype O:19 and
none were of serotype O:41. The most frequently observed
serotype was O:2. Strains reacting with one or more of the
antisera O:4, O:13, O:50, O:64, and O:65 are often related and
classified as O:4-complex. C. jejuni O:4-complex was observed
in four GBS patients and in one MFS patient. The O:2 sero-
type was found in two GBS- or MFS-related strains and in two
strains from family members of a GBS patient. C. jejuni O:2 is
the prevailing serotype in collections of strains from patients
with enteritis and, according to Oosterom et al. (21), accounts
for approximately 25% of the enteritis strains in The Nether-
lands. The Penner O serotyping scheme has been used in
several previous studies to characterize C. jejuni strains iso-
lated from patients with GBS or MFS, and those associated
with these conditions include O:1, O:2, O:4, O:4/50, O:5, O:10,
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O:16, O:19, O:23, O:37, O:41, O:44, and O:64 (18). We report
two new C. jejuni O serotypes, C. jejuni O:35 and O:13/65, that
have not been described previously in association with GBS.
The great variety of O serotypes that are found in the literature
and in this study confirm our previous suggestion that GBS and
MFS are not exclusively associated with a specific Penner O
serotype (9). However, C. jejuni serotype O:19 appears to be
overrepresented among strains isolated from patients with
GBS or MFS from the United States and Japan (16, 24). In a
Japanese study (24), serotype O:19 comprised 12 of 16 (75%)
of the GBS-related C. jejuni isolates, while in a U.S.-based
study (16), 2 of 7 (29%) were of serotype O:19. In both coun-
tries, this serotype is encountered in less than 3% of the C.
jejuni strains from patients with enteritis in the absence of
neurological involvement. In South Africa, 9 of 9 (100%) C.
jejuni isolates from GBS patients were of serotype O:41,
whereas this serotype was found in less than 2% of enteritis
control strains (12). In addition, some authors suggested that
Penner O:19 and O:41 strains, whether isolated from patients
with GBS or from enteritis patients without neurological in-
volvement, were clonally related, thereby indicating that these
strains were particularly virulent (6, 12, 24). The data pre-
sented here demonstrate that the overrepresentation of spe-
cific O serotypes, as reported by others, is a phenomenon not
seen in The Netherlands. Therefore, there would appear to be
much variety in the distribution of O serotypes in different
geographic locations. In addition to the more traditional phe-
notypic analysis, a variety of molecular typing techniques were
used to unravel the genomic differences or similarities of the C.
jejuni strains. The conclusions drawn from the results of sero-
typing were corroborated by the compiled data of the different
molecular typing methods. In general, the analysis of the GBS-
or MFS-related C. jejuni strains demonstrated substantial ge-
netic heterogeneity. No clustering of GBS- or MFS-related
strains was found, irrespective of the method used. Although
small clusters of related strains were found, strains from GBS
and MFS patients, as well as those from enteritis patients, were
present in these clusters. In some cases, a remarkable correla-
tion was found between the results of serotyping and the dif-
ferent molecular techniques. GB11, GB13, and GB14 were all
C. jejuni O:2, Lior 4 and showed great homology by PFGE,
RAPD, and RFLP. The two C. jejuni O:19, Lior 77 strains were
TABLE 1. Survey of serotyping (Penner and Lior) and genotyping data for C. jejuni strains associated with GBS and MFSa





GB1 1 UT A A A A A
GB2 UT 36 B B B B B
GB3 19/24 77 C A C B B
GB4 37 28 D C D C C
GB5 4/64 1 E D E D D
MF6 4/64 1 E1 E E1 E E
MF7 35 UT F F F F F
MF8 23/36 5 G G G G G
GB11 2 4 H H E1 H H1
GB13 2 4 H1 H1 H E H
GB14 2 4 H1 H1 E1 E H
GB15 5/34 UT I I I I I
GB16* 13/65 UT J J J B J
GB17 4/13/64 UT K K E E E
GB18 19 77 L L G B B
GB19 4/50 7 M M K J J
MF20 2 4 N N L K K
GB21 13/65 7 O O M L L
Serostrains
CCUG 10935 1 P P N D A1
CCUG 10936 2 Q Q O E H2
CCUG 10938 4 R R O M M
CCUG 10950 19 L1 S C N B
CCUG 10954 23 S T P D N
CCUG 10965 35 S1 U Q O O
CCUG 10966 36 T V R G G
CCUG 24868A 64 U W S P P
Enteritis
98-623 V X T G Q
98-624 W Y U Q R
98-652 X Z V R K
98-682 Y AA W S A
98-706 Z AA1 X I I
98-1033 AA BB Y T S
98-1039 BB CC Z U T
98-1040 CC DD AA V U
98-1087 DD EE BB T V
a The following were serotyped and genotyped: strains from The Netherlands (n 5 17) and Belgium (n 5 1), enteritis control strains (n 5 9), and Penner O serostrains
(n 5 8). *, Belgian strain; UT, untypeable.
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highly related by flaA and AFLP but had different PFGE and
RAPD patterns. Thus, although the discriminatory power of
the different techniques varies significantly, the clustering of
some strains was comparable.
Fujimoto et al. (6) recently determined the extent of genetic
variation among C. jejuni strains, including nine strains from
GBS patients. Although the strains were isolated from patients
residing in countries as diverse as the United States, Japan,
and Germany, the authors found that by flaA-RFLP and
RAPD analysis, at least five of nine GBS strains were closely
related. The five strains, however, were all of serotype O:19. In
addition, the data indicated that all O:19 strains, whether GBS
related or not, were clonally related. RAPD and RFLP of
other O serotypes, in contrast, were reported to be different
(6). In a recent Japanese study, 12 of 16 (75%) of the GBS-
related C. jejuni strains that had been serotyped were of sero-
type O:19 (24). flaA PCR-RFLP patterns of the 12 strains and
of enteritis-related C. jejuni O:19 were identical and distin-
guishable from other O serotypes (20). In the present study,
clonal relationships among the three O:19 strains were only
observed by AFLP. The two GBS strains had identical flaA
types, while the pattern was quite distinct from the O:19 sero-
type strain. Although this collection of Dutch GBS- or MFS-
related C. jejuni strains is characterized by a high degree of
heterogeneity, there were too few isolates from each type
present in the study. Therefore, the existence of clonality
among certain O serotypes cannot be excluded.
The heterogeneity among phenotypes and genotypes in the
present study may reflect the heterogeneity of clinical symp-
toms and anti-ganglioside antibodies in GBS patients. C. jejuni
infections are associated with a severe pure motor variant of
GBS (31) but have been reported in MFS patients, GBS pa-
tients with ophthalmoparesis, and patients with isolated abdu-
cens paresis as well (23, 27). The clinical heterogeneity may be
FIG. 1. FlaA PCR-RFLP patterns of 18 GBS- or MFS-related Campylobacter jejuni strains, 9 enteritis control strains, and 8 Penner O serostrains. The dendrogram
was constructed with band-based analysis and unweighted pair group method with averages clustering. The sizes of standard DNA fragments (in kilobase pairs) are
indicated below.
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related to the variety of ganglioside-like structures in the LPS
of GBS- or MFS-related C. jejuni, although this was not the
subject of study. No common molecular markers separating
pathogenic GBS or MFS from non-GBS- or non-MFS-related
enteritis strains were identified. Based on the present results, it
would be premature at this stage to dismiss the hypothesis of
the “bad bug that causes GBS.” The methods used in the study
may simply lack the power to detect the particular determi-
nants of C. jejuni strains related to GBS-MFS. Several authors
have provided evidence that the molecular basis of the mimicry
between C. jejuni and sialidated gangliosides resides in the LPS
fraction of Campylobacter (9, 17, 18). Analysis of genes in-
volved in the synthesis of LPS and the incorporation of sialic
acid may turn out to be of great importance to further clarify
the particularity of the C. jejuni strains involved in the patho-
genesis of GBS and MFS. Although ganglioside-like epitopes
have recently been described to be present in a significant
percentage of C. jejuni isolates from patients with uncompli-
cated enteritis (19), it seems likely that additional genotypic
methods may detect markers of pathogenicity in the near fu-
ture (32).
Finally, the results of serotyping and genotyping of the two
strains from a family outbreak of C. jejuni enteritis followed by
one case of GBS demonstrate a clonal relationship of the
strains and, therefore, suggest the importance of host factors in
the pathogenesis of GBS (1).
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